Aclaris Therapeutics, Inc. (0H8T.L)
USD 1.47
(-2.97%)
USD 1.47
(-2.97%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -97.35 Million USD | -14.33% |
| 2022 | -85.15 Million USD | -30.24% |
| 2021 | -65.38 Million USD | -34.76% |
| 2020 | -48.51 Million USD | 46.58% |
| 2019 | -90.83 Million USD | -8.77% |
| 2018 | -83.5 Million USD | -16.27% |
| 2017 | -71.82 Million USD | -61.22% |
| 2016 | -44.55 Million USD | -118.62% |
| 2015 | -20.37 Million USD | -138.81% |
| 2014 | -8.53 Million USD | -62.32% |
| 2013 | -5.25 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -13.63 Million USD | 33.89% |
| 2024 Q2 | -12.85 Million USD | 5.7% |
| 2023 Q3 | -22.53 Million USD | 31.23% |
| 2023 Q1 | -29.65 Million USD | -34.93% |
| 2023 FY | -114.52 Million USD | -34.5% |
| 2023 Q2 | -32.76 Million USD | -10.48% |
| 2023 Q4 | -20.61 Million USD | 8.5% |
| 2022 Q2 | -24.39 Million USD | -21.32% |
| 2022 FY | -85.15 Million USD | -30.24% |
| 2022 Q4 | -21.97 Million USD | -17.7% |
| 2022 Q3 | -18.67 Million USD | 23.45% |
| 2022 Q1 | -20.1 Million USD | 2.83% |
| 2021 Q2 | -13.2 Million USD | -9.23% |
| 2021 Q1 | -12.09 Million USD | 10.84% |
| 2021 Q3 | -19.39 Million USD | -46.87% |
| 2021 Q4 | -20.69 Million USD | -6.69% |
| 2021 FY | -65.38 Million USD | -34.76% |
| 2020 Q1 | -13.73 Million USD | 21.73% |
| 2020 FY | -48.51 Million USD | 46.58% |
| 2020 Q2 | -11.38 Million USD | 17.16% |
| 2020 Q3 | -9.83 Million USD | 13.55% |
| 2020 Q4 | -13.56 Million USD | -37.82% |
| 2019 Q3 | -22.86 Million USD | 6.15% |
| 2019 Q1 | -27.05 Million USD | -14.44% |
| 2019 FY | -90.83 Million USD | -8.77% |
| 2019 Q4 | -17.55 Million USD | 23.23% |
| 2019 Q2 | -24.36 Million USD | 9.94% |
| 2018 Q4 | -23.63 Million USD | -10.76% |
| 2018 FY | -83.5 Million USD | -16.27% |
| 2018 Q3 | -21.34 Million USD | -152.69% |
| 2018 Q1 | -30.08 Million USD | -20.64% |
| 2018 Q2 | -8.44 Million USD | 71.92% |
| 2017 Q1 | -12.93 Million USD | -17.8% |
| 2017 Q2 | -15.29 Million USD | -18.29% |
| 2017 Q3 | -18.75 Million USD | -22.63% |
| 2017 Q4 | -24.93 Million USD | -32.95% |
| 2017 FY | -71.82 Million USD | -61.22% |
| 2016 FY | -44.55 Million USD | -118.62% |
| 2016 Q4 | -10.97 Million USD | -1.52% |
| 2016 Q3 | -10.81 Million USD | 16.76% |
| 2016 Q2 | -12.98 Million USD | -33.17% |
| 2016 Q1 | -9.75 Million USD | -116.13% |
| 2015 Q1 | -2.62 Million USD | -1.04% |
| 2015 FY | -20.37 Million USD | -138.81% |
| 2015 Q3 | -10.64 Million USD | -309.86% |
| 2015 Q4 | -4.51 Million USD | 57.58% |
| 2015 Q2 | -2.59 Million USD | 1.26% |
| 2014 Q4 | -2.6 Million USD | 2.25% |
| 2014 Q1 | -1.63 Million USD | 0.0% |
| 2014 Q2 | -1.63 Million USD | 0.0% |
| 2014 Q3 | -2.66 Million USD | -62.86% |
| 2014 FY | -8.53 Million USD | -62.32% |
| 2013 FY | -5.25 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| uniQure N.V. | -282.87 Million USD | 65.583% |
| Agios Pharmaceuticals, Inc. | -391.48 Million USD | 75.131% |
| Amicus Therapeutics, Inc. | -73.49 Million USD | -32.469% |
| Atara Biotherapeutics, Inc. | -276 Million USD | 64.726% |
| bluebird bio, Inc. | -244.26 Million USD | 60.142% |
| Cara Therapeutics, Inc. | -121.49 Million USD | 19.867% |
| Imunon, Inc. | -21.03 Million USD | -362.934% |
| Editas Medicine, Inc. | -169.18 Million USD | 42.454% |
| IQVIA Holdings Inc. | 1.97 Billion USD | 104.924% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | 108.954% |
| Myriad Genetics, Inc. | -123.7 Million USD | 21.296% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | 138.803% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | -1747.732% |
| Verastem, Inc. | -92.08 Million USD | -5.726% |
| Walgreens Boots Alliance, Inc. | -14.07 Billion USD | 99.308% |
| Waters Corporation | 817.67 Million USD | 111.907% |
| Thermo Fisher Scientific Inc. | 6.85 Billion USD | 101.419% |
| Biogen Inc. | 1.29 Billion USD | 107.507% |
| Nektar Therapeutics | -137.42 Million USD | 29.156% |
| Perrigo Company plc | 151.9 Million USD | 164.093% |
| Dynavax Technologies Corporation | -37.02 Million USD | -162.928% |
| Illumina, Inc. | -1.06 Billion USD | 90.893% |
| Corbus Pharmaceuticals Holdings, Inc. | -45.07 Million USD | -115.978% |
| Iovance Biotherapeutics, Inc. | -460.55 Million USD | 78.861% |
| Heron Therapeutics, Inc. | -110.61 Million USD | 11.986% |
| Unity Biotechnology, Inc. | -44.66 Million USD | -117.962% |
| BioMarin Pharmaceutical Inc. | 194.44 Million USD | 150.07% |
| Sangamo Therapeutics, Inc. | -274 Million USD | 64.469% |
| Evolus, Inc. | -49.23 Million USD | -97.747% |
| Adicet Bio, Inc. | -152.03 Million USD | 35.965% |
| Regeneron Pharmaceuticals, Inc. | 4.04 Billion USD | 102.406% |
| Esperion Therapeutics, Inc. | -155.56 Million USD | 37.416% |
| FibroGen, Inc. | -281.81 Million USD | 65.454% |
| Agilent Technologies, Inc. | 1.35 Billion USD | 107.212% |
| OPKO Health, Inc. | -157.02 Million USD | 37.997% |
| Homology Medicines, Inc. | -48.25 Million USD | -101.755% |
| Geron Corporation | -193.94 Million USD | 49.801% |
| Alnylam Pharmaceuticals, Inc. | -282.17 Million USD | 65.498% |
| Exelixis, Inc. | 170.88 Million USD | 156.972% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 3.442% |
| Anavex Life Sciences Corp. | -55.75 Million USD | -74.613% |
| Intellia Therapeutics, Inc. | -515.29 Million USD | 81.106% |
| Zoetis Inc. | 3.06 Billion USD | 103.172% |
| Axsome Therapeutics, Inc. | -231.82 Million USD | 58.004% |
| Abeona Therapeutics Inc. | -48.2 Million USD | -101.985% |
| Vertex Pharmaceuticals Incorporated | 4.3 Billion USD | 102.26% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | -148.658% |
| Ionis Pharmaceuticals, Inc. | -353.73 Million USD | 72.477% |
| Sarepta Therapeutics, Inc. | -267.82 Million USD | 63.649% |
| Corcept Therapeutics Incorporated | 107.28 Million USD | 190.749% |
| Halozyme Therapeutics, Inc. | 337.57 Million USD | 128.84% |
| Blueprint Medicines Corporation | -486.27 Million USD | 79.979% |
| Insmed Incorporated | -709.62 Million USD | 86.281% |
| TG Therapeutics, Inc. | 20.63 Million USD | 571.851% |
| Incyte Corporation | 620.52 Million USD | 115.689% |
| Emergent BioSolutions Inc. | -726.4 Million USD | 86.597% |